STAAR Surgical Company (STAA) - Total Assets
Based on the latest financial reports, STAAR Surgical Company (STAA) holds total assets worth $456.36 Million USD as of September 2025. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. See STAAR Surgical Company (STAA) net assets for net asset value and shareholders' equity analysis.
STAAR Surgical Company - Total Assets Trend (1988–2024)
This chart illustrates how STAAR Surgical Company's total assets have evolved over time, based on quarterly financial data.
STAAR Surgical Company - Asset Composition Analysis
Current Asset Composition (December 2024)
STAAR Surgical Company's total assets of $456.36 Million consist of 72.2% current assets and 27.8% non-current assets.
| Asset Category | Amount (USD) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 28.3% |
| Accounts Receivable | $79.26 Million | 15.6% |
| Inventory | $43.30 Million | 8.5% |
| Property, Plant & Equipment | $0.00 | 0.0% |
| Intangible Assets | $0.00 | 0.0% |
| Goodwill | $1.79 Million | 0.4% |
Asset Composition Trend (1988–2024)
This chart illustrates how STAAR Surgical Company's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. For live market cap, price, and company overview, see STAAR Surgical Company stock valuation.
Key Asset Composition Facts
- Current vs. Non-Current Assets: STAAR Surgical Company's current assets represent 72.2% of total assets in 2024, an increase from 38.5% in 1988.
- Cash Position: Cash and equivalents constituted 28.3% of total assets in 2024, up from 0.6% in 1988.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 0.0% of total assets, unchanged from 0.0% in 1988.
- Asset Diversification: The largest asset category is accounts receivable at 15.6% of total assets.
STAAR Surgical Company Competitors by Total Assets
Key competitors of STAAR Surgical Company based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Gan & Lee Pharmaceuticals Co Ltd
SHG:603087
|
China | CN¥12.14 Billion |
|
Vizionfocus Inc.
TW:4771
|
Taiwan | NT$6.53 Billion |
|
MEDIMI AB AK
F:79T
|
Germany | €1.70 Million |
|
Ansell Ltd
AU:ANN
|
Australia | AU$3.32 Billion |
|
Nanosonics Ltd
AU:NAN
|
Australia | AU$272.48 Million |
|
SDI Ltd
AU:SDI
|
Australia | AU$141.20 Million |
|
Austco Healthcare Ltd
AU:AHC
|
Australia | AU$91.07 Million |
|
Trajan Group Holdings Ltd
AU:TRJ
|
Australia | AU$192.32 Million |
STAAR Surgical Company - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 5.21 | 5.99 | 5.25 |
| Quick Ratio | 4.35 | 5.38 | 4.81 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | $259.57 Million | $330.76 Million | $175.18 Million |
STAAR Surgical Company - Advanced Valuation Insights
This section examines the relationship between STAAR Surgical Company's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 2.30 |
| Latest Market Cap to Assets Ratio | 1.56 |
| Asset Growth Rate (YoY) | 4.3% |
| Total Assets | $509.52 Million |
| Market Capitalization | $794.79 Million USD |
Valuation Analysis
Above Book Valuation: The market values STAAR Surgical Company's assets above their book value (1.56x), reflecting positive investor sentiment about the company's future prospects.
Positive Asset Growth: STAAR Surgical Company's assets grew by 4.3% over the past year, showing continued investment in the company's operational capacity.
Annual Total Assets for STAAR Surgical Company (1988–2024)
The table below shows the annual total assets of STAAR Surgical Company from 1988 to 2024.
| Year | Total Assets | Change |
|---|---|---|
| 2024-12-31 | $509.52 Million | +4.26% |
| 2023-12-31 | $488.69 Million | +16.68% |
| 2022-12-31 | $418.82 Million | +21.12% |
| 2021-12-31 | $345.78 Million | +34.33% |
| 2020-12-31 | $257.42 Million | +24.04% |
| 2019-12-31 | $207.52 Million | +24.01% |
| 2018-12-31 | $167.34 Million | +146.33% |
| 2017-12-31 | $67.93 Million | +3.80% |
| 2016-12-31 | $65.44 Million | +3.95% |
| 2015-12-31 | $62.95 Million | +6.86% |
| 2014-12-31 | $58.91 Million | -4.88% |
| 2013-12-31 | $61.93 Million | +13.10% |
| 2012-12-31 | $54.76 Million | +11.74% |
| 2011-12-31 | $49.01 Million | +20.75% |
| 2010-12-31 | $40.59 Million | -30.84% |
| 2009-12-31 | $58.68 Million | +11.60% |
| 2008-12-31 | $52.58 Million | -2.95% |
| 2007-12-31 | $54.18 Million | +13.42% |
| 2006-12-31 | $47.77 Million | -9.45% |
| 2005-12-31 | $52.76 Million | +1.50% |
| 2004-12-31 | $51.97 Million | +10.07% |
| 2003-12-31 | $47.22 Million | +4.42% |
| 2002-12-31 | $45.22 Million | -31.28% |
| 2001-12-31 | $65.81 Million | -17.90% |
| 2000-12-31 | $80.15 Million | -6.03% |
| 1999-12-31 | $85.30 Million | +16.37% |
| 1998-12-31 | $73.30 Million | +17.47% |
| 1997-12-31 | $62.40 Million | +22.11% |
| 1996-12-31 | $51.10 Million | +31.70% |
| 1995-12-31 | $38.80 Million | +34.26% |
| 1994-12-31 | $28.90 Million | +53.72% |
| 1993-12-31 | $18.80 Million | +46.88% |
| 1992-12-31 | $12.80 Million | +36.17% |
| 1991-12-31 | $9.40 Million | -11.32% |
| 1990-12-31 | $10.60 Million | -20.30% |
| 1989-12-31 | $13.30 Million | -17.39% |
| 1988-12-31 | $16.10 Million | -- |
About STAAR Surgical Company
STAAR Surgical Company, together with its subsidiaries, designs, develops, manufactures, and sells implantable lenses for the eye and accessory delivery systems to deliver the lenses into the eye. The company provides implantable Collamer lens product family (ICLs) and laser-based procedures, such as LASIK to treat visual disorders, such as myopia, hyperopia, astigmatism, and presbyopia. It serve… Read more